Case-crossover and case-series analyses are 2 epidemiologic approaches that can be used to evaluate the association of exposures with acute events. Using a primary care database from the United Kingdom and these 2 statistical approaches, the authors investigated the impact of using benzodiazepines, nonbenzodiazepine hypnotics, beta-blockers, selective serotonin reuptake inhibitors, tricyclic antidepressants, opioids, and antihistamines on the risk of motor vehicle crashes in 1986-2004. For 49,821 individuals aged 18-74 years, involvement in a motor vehicle crash was documented. The outcome of the case-crossover analyses varied according to the choice of control period, so the case-series approach was preferred. The first 4 weeks of treatment with a combined acetaminophen and opioid preparation was associated with an increased risk of motor vehicle crash (incidence rate ratio ¼ 2.06, 99% confidence interval: 1.84, 2.32), as was use of an opioid alone (incidence rate ratio ¼ 1.70, 99% confidence interval: 1.39, 2.08) and benzodiazepines (incidence rate ratio ¼ 1.94, 99% confidence interval: 1.62, 2.32). Use of selective serotonin reuptake inhibitors, nonbenzodiazepine hypnotics, and antihistamines for more than 4 weeks was associated with motor vehicle crash, but shorter term use was not. The results obtained are broadly consistent with those from well-designed case-control studies and demonstrate how case-only techniques optimize the use of routinely collected data for epidemiologic studies.
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Investigations of the epidemiology of rare events commonly use case-control study designs. The effectiveness of such designs and the reliability of the results obtained depend primarily on the selection of an appropriate control group and the ability to measure and adjust for confounding factors. Over recent years, large primary care data sets have become available, offering a new resource for epidemiologists. These data sets often provide comprehensive coverage of a population's medical events, supplying readily available data that permit robust evaluation of rare events and exposures that may be difficult to study with more conventional study designs. However, traditional case-control comparisons are problematic because data on potential confounding factors are often limited, which makes identifying suitable control groups difficult and the results prone to residual confounding. Hence, case-only study designs have been developed, dispensing with the control group altogether and investigating associations between exposures and outcomes by comparing different time periods for each case. Because all individuals provide their own control data, defined temporally, differences between individuals that may confound the analysis are avoided.
Two main approaches have been proposed: the casecrossover design (1), which modifies case-control methodology; and the self-controlled case-series design (2, 3), which derives from cohort methods. In this study, we used these 2 approaches to assess the association between use of prescribed medications and the risk of motor vehicle crashes.
Driving performance may be impaired by the use of benzodiazepines (4), tricyclic antidepressants (5), opioids (6), beta-blockers (6), antihistamines (7), and nonbenzodiazepine sedatives such as zopiclone (8) , suggesting that users of these medications may be at increased risk of motor vehicle crash. Previous research suggests that the risk of involvement in a motor vehicle crash is increased by the use of sedatives such as zopiclone (9) and the benzodiazepines (9) (10) (11) (12) (13) (14) (15) , but studies of the effects of using tricyclic antidepressants (9, 11, 15) and opioids (11, 15) have produced inconsistent results.
Case-control studies of the effects of medication use on the risk of motor vehicle crashes represent a particular example of the difficulty in recruiting an appropriate control group from primary care databases. Such databases can provide information on medication usage and crash history, potentially reducing the difficulty and expense of conducting studies in this area, but typically lack important details such as driving behavior and annual mileage driven. Those who take prescribed medications may make fewer or shorter journeys than healthier individuals who do not, leading to underrepresentation in the case group and a systematic bias toward null (or even negative) associations in any analysis. Such bias can be eliminated by using case-only designs, which implicitly control for any differences between individuals that do not vary over time.
The case-crossover design is analogous to a matched case-control design. In a case-control study, individuals with the outcome of interest (cases) are compared with similar individuals without the outcome (matched controls). In a case-crossover study, all individuals have the outcome of interest, and the time period within each individual's record immediately before the outcome occurred (the at-risk, or ''case'' period) is compared with an earlier time period, of equal duration, when the outcome did not occur (the not-atrisk, or ''matched control'' period). Data are analyzed in a similar manner by using conditional logistic regression to compare the probability of exposure to the medication of interest between the at-risk and not-at-risk periods.
The main requirements are that the at-risk and control periods be relatively short and close together in time (to avoid introducing bias due to temporal effects). An important advantage of case-crossover designs is that they are relatively easy to implement, and, because each individual provides his or her own control period, confounding due to differences between individuals is avoided. However, to provide useful data, the case-crossover results are tested by using sensitivity analyses to ensure they do not depend on the choice of control period. In situations in which the probability of exposure and outcome may both vary over time (e.g., seasonally), sensitivity testing is particularly important.
The self-controlled case-series design was originally developed to enable study of adverse reactions to childhood vaccinations (1, 2) , where high levels of coverage in the population make the selection of a control group impractical, but this design has been applied successfully in a variety of other situations, including several pharmacoepidemiologic studies using primary care medical record data sets (16) (17) (18) (19) . The case-series design involves dividing individual patient follow-up time into exposed and unexposed periods (which may vary in duration), between which the incidence rates of the outcome of interest are compared. Similar to the case-crossover method, the case-series approach implicitly controls for the effects of intraindividual confounding factors such as risky lifestyle behavior that may be important with regard to the outcome of interest, although it again assumes that this factor remains constant over the period of observation. Case-series analyses are more complicated to implement and are more computationally demanding than case-crossover analyses, but they provide another analytical approach for data sets in which the case-crossover analysis may not be appropriate. In addition, compared with the case-crossover method, the case-series method has the benefit of permitting exploration of changes in risk with duration of exposure, and it approaches cohort designs in terms of statistical power (1) .
We used data from a primary care database from the United Kingdom to compare use of these 2 analytical approaches to examine the association between involvement in a motor vehicle crash and prescription medication use. The automated data available to define drug exposures was used.
MATERIALS AND METHODS

Study population
Data for this study were obtained from The Health Improvement Network (THIN), a large database of prospectively collected primary care records that contain the date and details of prescriptions, including dose and formulation. The version of THIN used in this study comprises data collected up to November 2004 at 255 general practices in the United Kingdom.
The study population comprised all individuals with a first recorded motor vehicle crash at least 1 year after the start of their computerized medical record who were aged 18-74 years at the time of the event and for whom continuous data from entry to exit were available in the database. Individuals coded as a nondriving participant at the time of the accident were excluded. When patients register with a new practitioner or a practitioner converts from paper-based to computerized record keeping, past diagnoses and events may be inadvertently recorded by using the date of entry into the new system, even though the event may have occurred a long time ago (20) . Therefore, the first year of each individual's record was excluded from each analysis to address this issue and ensure that the included motor vehicle crash records related to incident events. The follow-up period was defined as ending on the day on which the last data were collected at their general practice or the date of death or transfer to another practice (if applicable).
Case-crossover analysis
The study population included all individuals involved in a motor vehicle crash during the qualifying period of follow-up. The at-risk period for each patient in the study population was defined as the 4 weeks immediately before the date of a motor vehicle crash. The day on which a motor vehicle crash occurred was excluded from this period in case any of the medications of interest were prescribed as a consequence of involvement in a crash. The case-crossover method assumes that the baseline risk for an exposure is constant, and this assumption was tested in a sensitivity analysis by using 5 successive 4-week control periods starting immediately prior to the at-risk period ( Figure 1 ).
Records relating to prescriptions for any benzodiazepine, nonbenzodiazepine hypnotic, beta-blocker, opioid, acetaminophen/opioid compound analgesic, tricyclic antidepressant, selective serotonin reuptake inhibitor (SSRI), or antihistamine preparation listed in the British National Formulary were extracted for each individual. Exposure to each class of medication was defined by using binary variables indicating the presence or absence of a relevant prescription dated within each defined period. The modal interval between prescriptions for these medications in THIN records was found to be 4 weeks; hence, this duration was chosen for the at-risk and control periods. Data were analyzed by using conditional logistic regression models in Stata SE version 9 software (Stata Corporation, College Station, Texas) for Windows XP (Microsoft Corporation, Redmond, Washington).
Case-series analysis
As in the previous analysis, data on prescriptions relating to any of the medications of interest were extracted for each individual in the study population. These records were grouped into courses of treatment. THIN prescription records do not always contain details on the length of time during which the medication should be used, so courses of treatment were defined according to the interval between prescriptions. The modal interval between prescriptions was found to be 4 weeks, with further discernable peaks at 8, 12, and 16 weeks, in line with normal prescribing practice in the United Kingdom. The conservative assumption was therefore made that prescriptions were part of an ongoing course of treatment if they were dated within 16 weeks of a prior prescription for a drug in the same class. The outcome event of interest was the first motor vehicle crash. Subsequent events were not included in the analysis.
The available follow-up time for each individual was classified into the following 6 categories based on their exposure to medications of interest ( Figure 2 ).
Time when unexposed to the medication of interest (baseline). 2. A 4-week period up to and including the date of the start
of each course of treatment. Since many of the medications of interest could be used to treat anxiety or pain caused by a motor vehicle crash, it is necessary to include this category, a preexposure time period that removes any motor vehicle crashes that might have led to the issue of a prescription from the calculation of the baseline incidence rate, preventing any spurious inflation of this quantity. The number of prescriptions for any medication of interest issued on each day subsequent to the date of accident was inspected graphically and was found to decline, from a sharp increase on the day of the accident (but not before) to a steady baseline within 4 weeks; hence, this duration was chosen for this category. 3. The 4 weeks immediately following the start of a course of treatment (starting on the day after the date of the first prescription): acute exposed time. 4. The remainder of that course of treatment, ending 4 weeks after the last prescription: chronic exposed time. 5. The first 12 weeks after the end of each course of treatment. 6. The second 12 weeks after the end of each course of treatment.
The division of exposed time into 2 categories enables investigation of whether any changes in the risk of motor vehicle crash are short-lived (while patients adjust to their medication), develop over time (only become apparent with extended use), or are constant. The fifth and sixth periods were included to investigate withdrawal effects; most individuals will have discontinued their use of the medication by the start of the fifth period, while those with 8-, 12-, or 16-week prescriptions will have discontinued use by the start of the sixth period. For cases who began a new course of treatment during either of these last 2 periods, the exposure statuses associated with the new course took preference.
Data were analyzed by using Stata 9SE software for Windows XP. Separate data sets dividing individual followup time into the defined exposure categories were created for each class of medication. Individuals not exposed at any time were excluded from each analysis. Fixed-effects Poisson regression models were used to calculate incidence rate ratios (IRRs) comparing the incidence rates of motor vehicle crash in each exposure category with the incidence rate during the baseline period. The case-series design does not eliminate confounding due to risk factors such as age, which vary over time. We therefore adjusted our analyses by 3-year age groups and calculated 99% confidence intervals.
Using a sample-size formula based on the signed root likelihood ratio (as proposed by Musonda et al. (21)), we calculated that, to detect an incidence rate ratio of 1.2 in the first 28 days after prescription with 95% power and at the 5% significance level, we would require 3,169 exposed cases. Within each drug class, the effects of using the most common individual medications on the risk of motor vehicle crash were calculated. These data are provided in this paper for illustrative purposes only (several involved fewer than the calculated minimum number of cases) and should be interpreted cautiously.
RESULTS
During the qualifying period of follow-up, 49,821 individuals had a first recorded motor vehicle crash (Figure 3) . The median duration of follow-up was 9.6 years. Table 1 shows the results of the case-crossover analysis. The magnitude of association between exposure to medication and the outcome often varied, depending on the control time period selected. The results of the case-series analyses are given in Table 2 . All categories of medication showed a marked association with involvement in a motor vehicle crash in the 28 days up to and including the date of first prescription of a course of treatment, consistent with the issue of prescriptions as a consequence of involvement in a motor vehicle crash.
The initiation of opioid treatment was associated with an increased risk of motor vehicle crash (IRR ¼ 1.70, 99% confidence interval (CI): 1.39, 2.08) that persisted throughout the remainder of treatment (IRR ¼ 1.29, 99% CI: 1.08, 1.54) but was not observed after withdrawal of treatment. Similarly, the use of acetaminophen/opioid compound analgesic preparations was associated with a raised risk of motor vehicle crash in the first 4 weeks of treatment (IRR ¼ 2.06, 99% CI: 1.84, 2.32), which increased with extended exposure (IRR ¼ 2.66, 99% CI: 2.40, 2.95) before decreasing to unity by the second 12-week postexposure period.
Benzodiazepine use was associated with an increased risk of motor vehicle crash (IRR ¼ 1.94, 99% CI: 1.62, 2.32) in the first 4 weeks of treatment, and risk increased with extended use (IRR ¼ 2.38, 99% CI: 2.01, 2.81) before decreasing to close to unity in the second 12-week postexposure period. Short-term use of nonbenzodiazepine hypnotics was not associated with an increased risk of motor vehicle crash (IRR ¼ 1.06, 99% CI: 0.73, 1.54), but longer-term use was associated with a modest increased risk (IRR ¼ 1.37, 99% CI: 1.05, 1.79), which did not persist after the withdrawal of treatment.
Short-term use of SSRIs was not associated with an increased risk of motor vehicle crash (IRR ¼ 0.92, 99% CI: 0.75, 1.12), but extended use was associated with a small increased risk (IRR ¼ 1.16, 99% CI: 1.06, 1.28) that decreased after the withdrawal of treatment to close to unity by the second 12-week postexposure period. We found no effect of receiving a prescription for antihistamines on short-term risk of motor vehicle crash, but extended use of antihistamines was associated with an increased risk of motor vehicle crash (IRR ¼ 1.21, 99% CI: 1.04, 1.41).
The use of beta-blockers and tricyclic antidepressants was not associated with an increased risk of motor vehicle crash.
DISCUSSION
We used 2 self-controlled analytical approaches and a primary care data set to investigate the effect of being prescribed a variety of medicines on the risk of involvement in a motor vehicle crash, conducting the largest known study of these associations to date. The results from the casecrossover analysis were found to vary according to the choice of control period, suggesting that this method does not represent the optimal analytical approach to investigate these associations in these data. The results of the caseseries analysis suggest that the risk of motor vehicle crash is increased by the use of benzodiazepines, opioids, and compound analgesic preparations containing acetaminophen and an opioid for the duration of their usage, the risk decreasing once the medication is discontinued. In addition, we detected a modest increased risk of motor vehicle crash for those using nonbenzodiazepine hypnotics, SSRIs, and antihistamines for longer than 4 weeks. There was no evidence of increased risk of motor vehicle crash for users of tricyclic antidepressants, for users of beta-blockers, or following withdrawal from any of the medications under investigation. Abbreviations: CI, confidence interval; OR, odds ratio; SSRIs, selective serotonin reuptake inhibitors. * P < 0.01. a Odds ratio for exposure to the medication of interest between the at-risk period (1-28 days prior to motor vehicle crash) and the control period. b Years denote the maximum range. The actual start and end of follow-up for each individual is dependent on the period during which he or she was alive, registered, and eligible for inclusion in the study.
c Zopiclone, zolpidem, chlormezanone, zaleplon. d Co-codamol, co-proxamol, co-dydramol. Abbreviations: CI, confidence interval; IRR, incidence rate ratio; SSRIs, selective serotonin reuptake inhibitors. a Exposure time periods: 2 ¼ 4-week period up to and including the date of the prescription; 3 ¼ 4-week period following the first prescription of a course of treatment; 4 ¼ remainder of exposed time; 5 ¼ 12-week period following the end of exposure; 6 ¼ second 12-week period following the end of exposure. Period 1 (not shown) is the referent period and represents time when subjects were unexposed to the medication of interest.
b Years denote the maximum range. The actual start and end of follow-up for each individual is dependent on the period during which he or she was alive, registered, and eligible for inclusion in the study.
c Individual medication totals do not equate to the category total because some subjects received more than one medication in each category. d Zopiclone, zolpidem, chlormezanone, zaleplon. e Co-codamol, co-proxamol, co-dydramol. The analyses presented in this paper demonstrate how case-only designs can be used to conduct epidemiologic studies in data sets in which case-control methodologies are inappropriate because of between-individual confounding and bias. The results obtained are broadly consistent with those from previous studies of this topic (refer to the discussion below), and the additional data provided by use of the case-series method shed new light on the temporal trends in changes in motor vehicle crash risk associated with medication use.
Because the results obtained from the case-crossover method using the example of benzodiazepines gave odds ratios that varied from 1.06 to 1.41 according to the control period selected, we considered that the data from the caseseries analysis were more useful in providing insights into the associations between medications prescribed and motor vehicle crashes. However, the case-crossover method remains a useful epidemiologic technique that is easier to implement, less computationally intensive, more intuitive to many, and, in some ways, more flexible than the caseseries design, and it has been used successfully in other data sets to investigate the impact of medication use on the risk of motor vehicle crash (9) .
It is important to consider the limitations of case-only analyses. The use of such designs establishes the temporal relation between exposure and outcome (motor vehicle crash), but they cannot (in pharmacoepidemiologic studies) distinguish between the effects of the disease that necessitated prescription of a medication and the direct effects of the drugs themselves because these effects are, by their very nature, coincident. It is also possible that unrecorded, sporadic exposures that increase the risk of the outcome may occur more frequently around the time of exposure (e.g., an increase in alcohol consumption may accompany depression and therefore the prescription of an antidepressant) and confound the observed associations. From a clinical perspective, however, it is important to consider the combined effects of illness, medication use, and associated lifestyle changes, so these results will assist both practitioners and patients in making informed decisions about driving safety.
Finally, in the case-series analysis, the 4-week period prior to drug prescription (period 2) was designed to exclude from baseline person-time any motor vehicle crashes that may have led to a drug prescription for pain control or relief from anxiety. The high rate ratios observed in this period unsurprisingly suggest that some of these medications are prescribed in response to a motor vehicle crash, and they demonstrate the importance of such adjustments.
Comparison with previous studies
Our findings in relation to benzodiazepines are consistent with those of previous studies (9) (10) (11) (12) (13) (14) (15) , which suggest that current use of these medications approximately doubles the risk of accident (4) . It is notable that the largest association was between diazepam use and motor vehicle crash. Diazepam is commonly prescribed as an anxiolytic (22) and is taken during the daytime, when individuals are more likely to drive, whereas temazepam and nitrazepam are more likely to be used as nighttime hypnotics.
In common with Barbone et al. (9), we detected an increased risk of motor vehicle crash for those taking nonbenzodiazepine hypnotics, but, in our population, this effect was observed following only prolonged exposure. We also detected a modest increased risk for longer term users of SSRIs that was not observed in the earlier study, perhaps because our analysis had greater statistical power to detect this small effect.
The results of previous studies investigating the impact of opioids and tricyclic antidepressant use are conflicting (9, 11, 15) ; however, in both instances, our results concur with the outcome of the larger study (11, 15) . Our findings with respect to antihistamines and beta-blockers should be interpreted cautiously. Many antihistamines are available without prescription in the United Kingdom, so it is unlikely that we had complete exposure data on these medications. Betablockers are normally prescribed as chronic (''rest-of-life'') medications, which may violate the assumption that duration of exposure is short relative to the overall period of follow-up, and were included at the request of the ethical review panel that approved the present study.
Limitations of this analysis
Several further limitations are specific to this application and data source. We tested the effect of a variety of exposures on the risk of involvement in a motor vehicle crash, which could have produced spurious associations; however, use of 99% confidence intervals reduced the likelihood that the observed associations are due to chance. We were unable to determine whether patients collected their medication or used it as prescribed. We did not have data on duration of the treatment prescribed, and, because some prescriptions may be for as short a period as 1-2 weeks, our analysis may have underestimated the true size of the association with motor vehicle crash because of misclassification of exposure time. We were unable to investigate dose-response associations for any of the medications under investigation because a significant proportion of THIN prescription records do not contain usable dosage information. In addition, we were able to study only those motor vehicle crashes that were reported to the general practitioner, although these are likely to be events that caused morbidity and hence are most important from a public health perspective.
We were also unable to determine whether individuals in our population were actually driving at the time of their collisions; only a small minority of motor vehicle crash records in THIN differentiate between drivers, passengers, and pedestrians (although we excluded nondrivers when suitably detailed records were available). If the effect of taking medication on motor vehicle crash risk is indeed causal and due to impaired driving performance, the presence of nondrivers in our population would lead us to underestimate the true effects.
We cannot exclude the possibility that patients seeking treatment for other illnesses for which the medications of interest are eventually prescribed may have reported some Practical Application of Self-controlled Analyses 767 minor events that would not otherwise have been recorded; however, if this issue were serious, we would expect to have observed increased incidences of motor vehicle crash related to all medications. In fact, we observed no increased incidence of motor vehicle crash among users of beta-blockers and tricyclic antidepressants. We did not have available data on prescriptions from sources other than the primary care centers and cannot exclude the possibility that medication may have been obtained from elsewhere, but this possibility would introduce random error to our analysis and tend to reduce the size of the effect seen. Finally, we were unable to account for the impact of patient behavior following receipt of a prescription, and some patients may have refrained from driving while using the medications of interest, leading to an underestimate of the associated risk.
Summary
This study demonstrates the use of case-only methods to eliminate the effects of between-individual confounding and permit use of data sources unsuitable for conducting traditional case-control studies. The results obtained are broadly consistent with those from well-designed case-control studies, and they provide additional information about the time course of changes in risk. We anticipate that as large longitudinal data sets become more widely available, familiarity with these techniques will become increasingly important in the field of epidemiology.
